T-cell depletion

T-cell depletion

A therapeutic manoeuvre (e.g., diphtheria toxin injection), which is meant to reduce T cells that play a key role in immune response. T-cell depletion of a donor’s bone marrow graft reduces the risk of graft versus host disease (GVHD).

In Japan, there has a tendency to select tacrolimus rather than cyclosporine for GVHD prophylaxis, and the cumulative incidence of chronic GVHD was higher in NHL patients with tacrolimus plus methotrexate than in those with cyclosporine plus methotrexate for GVHD prophylaxis.[24] Many research reported that chronic GVHD significantly reduced by GVHD prophylaxis accompanied with ATG.[33] However, some studies showed in vivo T-cell depletion with ATG increased lymphoma recurrence rate and early opportunistic virus infection.

ATOR-1015 is a next generation CTLA-4 bispecific antibody developed for tumour-directed immunotherapy with increased capability of regulatory T-cell depletion. ATOR-1015 binds to the checkpoint receptor CTLA-4 and the co-stimulatory receptor OX40.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.